eprintid: 10161268 rev_number: 7 eprint_status: archive userid: 699 dir: disk0/10/16/12/68 datestamp: 2022-12-05 11:59:01 lastmod: 2022-12-05 11:59:01 status_changed: 2022-12-05 11:59:01 type: article metadata_visibility: show sword_depositor: 699 creators_name: Bartoli, Francesco creators_name: Riboldi, Ilaria creators_name: Bachi, Bianca creators_name: Calabrese, Angela creators_name: Moretti, Federico creators_name: Crocamo, Cristina creators_name: Carra, Giuseppe title: Efficacy of Cannabidiol for Delta-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review ispublished: pub divisions: UCL divisions: B02 divisions: C07 divisions: D79 keywords: Cannabidiol; Δ-9-tetrahydrocannabinol; schizophrenia; psychotic disorders; cannabis use disorder; dual diagnosis note: © 2021 by the Authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). abstract: Although cannabis’ major psychoactive component, ∆-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders. date: 2021-03-02 date_type: published publisher: MDPI official_url: https://doi.org/10.3390/jcm10061303 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1855587 doi: 10.3390/jcm10061303 medium: Electronic pii: jcm10061303 lyricists_name: Carra, Giuseppe lyricists_id: GCARR70 actors_name: Carra, Giuseppe actors_id: GCARR70 actors_role: owner full_text_status: public publication: Journal of Clinical Medicine volume: 10 number: 6 article_number: 1303 pages: 10 event_location: Switzerland citation: Bartoli, Francesco; Riboldi, Ilaria; Bachi, Bianca; Calabrese, Angela; Moretti, Federico; Crocamo, Cristina; Carra, Giuseppe; (2021) Efficacy of Cannabidiol for Delta-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review. Journal of Clinical Medicine , 10 (6) , Article 1303. 10.3390/jcm10061303 <https://doi.org/10.3390/jcm10061303>. Green open access document_url: https://discovery-pp.ucl.ac.uk/id/eprint/10161268/1/jcm-10-01303.pdf